Breaking News
1 day ago
Vaibhavi M.

Cognition Therapeutics gains FDA alignment on zervimesine Phase 3 design for DLB psychosis, with NPI as a novel primary endpoint and a mid-2027 program start.
Vaibhavi M.

Biocon wins Malaysia MoH insulin supply contracts worth over Rs. 515 crore, covering human insulin, glargine, and aspart via Duopharma Biotech.
Simantini Singh Deo

Sun Pharma joins the 2026 S&P Dow Jones Best-in-Class World Index, one of 317 global companies and 25 from India recognised for industry-leading sustainability performance.
Mrudula Kulkarni
FDA's final DHT guidance sets binding expectations for remote data acquisition in clinical trials, affecting protocol design and submission strategy.
Simantini Singh Deo
